Business Context and Reporting Period
Company: Biodesix, Inc. (BDSX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Biodesix is a diagnostic solutions company focused on personalized diagnostics for lung disease. Revenue is derived from two primary segments: (1) Lung Diagnostic Testing, providing blood-based tests for lung nodule risk assessment and treatment guidance; and (2) Development Services, offering diagnostic testing and consulting to biopharmaceutical and life sciences companies.
Key Financial Metrics
| Metric | 2025 (Actual) | 2024 (Actual) | Change |
|---|---|---|---|
| Total Revenue | $88.5 million | $71.3 million | +24% |
| Gross Margin | 81% | 78% | +300 bps |
| Operating Expenses | $116.4 million | $105.8 million | +10% |
| Net Loss | $(35.3) million | $(42.9) million | -18% (Improvement) |
| Cash and Cash Equivalents | $19.0 million | $26.2 million | Not Applicable |
| Long-Term Debt (Principal) | $50.0 million | $40.0 million | +10.0 million |
Note: The filing text does not provide a specific value for Free Cash Flow; however, Net Cash Used in Operating Activities was $(23.3) million for 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24% year-over-year. Lung Diagnostic Testing revenue grew 22% to $79.2 million, driven by a 15% increase in test volume (62,600 tests) and improved average revenue per test. Development Services revenue surged 41% to $9.3 million due to new agreements and delivery on contracted business.
- Margin Expansion: Gross margin improved to 81% from 78% in 2024, attributed to workflow optimizations and decreased costs per test.
- Expense Management: Operating expenses (excluding direct costs) grew only 10% despite 24% revenue growth, demonstrating operating leverage. Share-based compensation expense decreased 38% to $4.1 million.
- Debt Financing: The company drew the final $10.0 million tranche of its Perceptive Term Loan Facility in May 2025, bringing total outstanding principal to $50.0 million.
- Stock Split: A 1-for-20 reverse stock split was effected on September 15, 2025, to regain compliance with Nasdaq listing standards.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management highlighted strong commercial momentum, particularly in the Nodify Lung Nodule Risk Assessment tests. The company expects continued operating leverage as the expanded sales team matures. Future growth drivers include increased payer coverage, expansion of the sales force, and the commercialization of new pipeline tests (e.g., Molecular Residual Disease and ESR1 monitoring).
Key Risks & Contingencies:
- Profitability: The company has a history of net losses and expects to continue incurring losses for the foreseeable future. It had an accumulated deficit of approximately $497.8 million as of December 31, 2025.
- Liquidity & Capital Needs: While the company raised $14.7 million in subsequent ATM sales and extended its debt maturity to 2028, it may need to raise additional capital to fund operations and growth.
- Reimbursement: Revenue is heavily dependent on third-party payer reimbursement. Medicare accounted for 32% of total revenue in 2025. Changes in reimbursement rates or coverage policies could materially impact financial results.
- Supply Chain: The company relies on single-source suppliers for critical components (e.g., Bio-Rad for GeneStrat tests), creating vulnerability to supply disruptions.
- Regulatory: While the FDA rescinded a rule to actively regulate Laboratory Developed Tests (LDTs) in September 2025, future regulatory changes remain a risk.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $19.0 million cash balance plus subsequent ATM proceeds against the $35.3 million annual burn rate and upcoming debt obligations.
- Debt Covenants: Confirm compliance with the Perceptive Term Loan Facility covenants, specifically the minimum cash balance ($2.5 million) and minimum net revenue thresholds.
- Reimbursement Trends: Monitor the stability of Medicare and commercial payer reimbursement rates, given the 32% revenue concentration in Medicare.
- Supply Chain Resilience: Assess the status of second-source qualification for critical single-source suppliers (Bio-Rad, Freenome/Oncimmune).
- Stock Liquidity: Review post-split trading volume and compliance with Nasdaq minimum bid price requirements.